Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The ob...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Daly, A.F., Tichomirowa, M.A., Petrossians, P., Heliövaara, E., Jaffrain-Rea, M.-L., Barlier, A., Naves, L.A., Ebeling, T., Karhu, A., Raappana, A., Cazabat, L., De Menis, E., Montañana, C.F., Raverot, G., Weil, R.J., Sane, T., Maiter, D., Neggers, S., Yaneva, M., Tabarin, A., Verrua, E., Eloranta, E., Murat, A., Vierimaa, O., Salmela, P.I., Emy, P., Toledo, R.A., Sabaté, M.I., Villa, C., Popelier, M., Salvatori, R., Jennings, J., Longás, Á.F., Aizpún, J.I.L., Georgitsi, M., Paschke, R., Ronchi, C., Valimaki, M., Saloranta, C., De Herder, W., Cozzi, R., Guitelman, M., Magri, F., Lagonigro, M.S., Halaby, G., Corman, V., Hagelstein, M.-T., Vanbellinghen, J.-F., Barra, G.B., Gimenez-Roqueplo, A.-P., Cameron, F.J., Borson-Chazot, F., Holdaway, I., Toledo, S.P.A., Stalla, G.K., Spada, A., Zacharieva, S., Bertherat, J., Brue, T., Bours, V., Chanson, P., Aaltonen, L.A., Beckers, A.
Formato: JOUR
Materias:
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_0021972X_v95_n11_pE373_Daly
Aporte de:
Descripción
Sumario:Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. Copyright © 2010 by The Endocrine Society.